Hepatocellular carcinoma

The Lancet

Volumn 380, Issue 9840, 2012, Pages 469-470

  Van Den Bosch, Maurice A A J ^a   Defreyne, Luc ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MICROSPHERE; YTTRIUM 90;

CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HUMAN; LETTER; LIVER CELL CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); LIVER TUMOR; NOTE;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS;

EID: 84864764922     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61284-7     Document Type: Letter

References (3)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-55.
2. Vente MA, Wondergem M, Van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-Analysis. Eur Radiol 2009; 19: 951-59.
3. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-Term outcomes. Gastroenterology 2010; 138: 52-64.